有针对性的教育干预可以提高高风险心房患者的口服抗凝率
Roop Dutta1, John G Ryan2, Sally Hurley1
1St. Elizabeth's Medical Center, Boston, Massachusetts.
Heart rhythm O2
|June 6, 2024
概括
一项有针对性的教育干预措施改善了高风险中风的心房动 (AF) 患者的口服抗凝率. 这项研究强调了为初级保健提供者提供专注教育,以提高OAC处方的有效性.
科学领域:
- 心脏病学 心脏病学
- 主要护理医学 医疗保健
- 医疗保健服务研究 医疗服务研究
背景情况:
- 前庭动 (AF) 管理在很大程度上依赖于抗凝药来预防中风.
- 口服抗凝剂 (OAC) 是一个关键的策略,在美国大型卫生系统中,其比率超过80%.
- 鉴定和解决高风险AF患者OAC的障碍仍然至关重要.
研究的目的:
- 通过有针对性的教育干预,提高AF患者的OAC率.
- 该干预特别关注具有历史低OAC处方率的初级保健提供者 (PCP).
- 这旨在改善AF患者中风风险管理.
主要方法:
- 主要护理临床医生根据不接受抗凝药的高风险AF患者的比例进行了分层.
- 最低率的临床医生被分配到一个接受电子邮件指南总结的教育组 (EG).
- 一个比较组 (CG) 接受了标准护理;结果在6个月的随访期间进行了评估.
主要成果:
- 基线分析显示,与CG (13.64%;P = .001) 相比,EG (20.65%) 的高风险AF患者未接受治疗的比例显著更高.
- 在干预后,未经治疗的高风险AF患者在两组都下降了 (EG: 15.47%,P = .047;CG: 10.14%,P = .07).
- 与CG (3.50%) 相比,EG在未接受治疗的患者 (5.19%) 中显示出更大的绝对减少.
结论:
- 针对PCP的有针对性的教育计划与高风险AF患者的OAC率增加有关.
- 这种干预策略在改善预防中风的抗凝药处方方面被证明是有效的.
- 专注的教育可以对临床实践和AF管理中的患者结果产生积极影响.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
519
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
519


